Iatrogenic botulism after botulinum toxin type A injections

Clinical Neuropharmacology

Volumn 33, Issue 3, 2010, Pages 158-160

  Coban, Arzu ^a   Matur, Zeliha ^b   Hanagasi, Hasmet A ^b   Parman, Yesim ^b  

^a BALIKESIR UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Blepharospasm; Botulinum toxin A; Iatrogenic botulism; Spasticity

Indexed keywords

ANTIINFECTIVE AGENT; BOTULINUM TOXIN A; PYRIDOSTIGMINE;

ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; BLEPHAROSPASM; BOTULISM; CASE REPORT; DIPLOPIA; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSARTHRIA; DYSPHAGIA; DYSPNEA; ELECTROMYOGRAM; FATIGUE; FEMALE; GASTROCNEMIUS MUSCLE; GENERALIZED DYSTONIA; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MUSCLE WEAKNESS; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SPASTICITY; TIBIALIS POSTERIOR MUSCLE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL DISORDER;

ADULT; AGED; ANTI-DYSKINESIA AGENTS; BLEPHAROSPASM; BOTULINUM TOXIN TYPE A; BOTULISM; DRUG MONITORING; FEMALE; HUMANS; IATROGENIC DISEASE; MUSCLE SPASTICITY; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953154709     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181d479e0     Document Type: Article

References (22)

1. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: the clinical usefulness of botulinum toxin-A in treating neurologic disorders. Neurology 1990;40:1332-1336.
2. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997;6:146-168.
3. Olney RK, Aminoff MJ, Gelb DJ, et al. Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 1988;38:1780-1783.
4. Bhatia KP, Munchau A, Thompson PD, et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry 1999;67:90-93.
5. Bakheit AM, Ward CD, McLellan DL. Generalized botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry 1997;62:198.
6. Duffey P, Brown C. Iatrogenic botulism in an amateur weight-lifter. Mov Disord 2006;21:1056.
7. Souayah N, Karim H, Kamin SS, et al. Severe botulism after focal injection of botulinum toxin. Neurology 2006;67:1855-1856.
8. Chertow DS, Tan ET, Maslanka SE, et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 2006;296:2476-2479.
9. Omprakash HM, Rajendran SC. Botulinum toxin deaths: what is the fact? J Cutan Aesthet Surg 2008;1:95-97.
10. Ault A. New botulinum toxin injection warnings issued: postinjection symptoms include dysphagia, ptosis and shortness of breath, according to the FDA. Skin Allergy News 2008;39:13.
11. Barclay L. Respiratory compromise, death may be linked to botulinum toxin. Medical alerts. February 8, 2008. Available at: http://www.medscape.com. Accessed March 14, 2008.
12. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med 1998;129:221-228.
13. Cherington M. Clinical spectrum of botulism. Muscle Nerve 1998;21:701-710.
14. Hughes JM, Blumenthal JR, Merson MH, et al. Clinical features of types A and B food-borne botulism. Ann Intern Med 1981;95:442-445.
15. Girlanda P, Vita G, Nicolosi C, et al. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 1992;55:844-845.
16. Garner CG, Straube A, Witt JN, et al. Time course of distant effects of local injections of botulinum toxin. Mov Disord 1993;8:33-37.
17. Konstanzer A, Ceballos-Baumann AO, Dressnandt J, et al. Local injection treatment with botulinum toxin A in severe arm and leg spasticity. Nervenarzt 1993;64:517-523.
18. Münchau A, Bhatia KP. Regular review: uses of botulinum toxin injection in medicine today. BMJ 2000;320:161-165.
19. De Almeida AT, De Boulle K. Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. J Cosmet Laser Ther 2007;9:17-22.
20. Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol 2006;13:2-10.
21. Foster KA, Bigalke H, Aoki KR. Botulinum neurotoxin V from laboratory to bedside. Neurotoxicity Res 2006;9:133-140.
22. Jankovic J, Schwartz KS. Clinical correlates of response to botulinum toxin injections. Arch Neurol 1991;48:1253-1256.